The Egyptian Drug Authority (EDA) has announced the development of new mechanisms to facilitate procedures for registering human drugs.

EDA Spokesperson Ali Al-Ghamrawi said that it was decided to allow pharmaceutical companies that obtained a preliminary registration notification to submit a complete registration file, after completing all necessary studies.

He pointed out that this procedure allows companies to adjust their conditions and complete all their data to complete registration procedures.

EDA has taken several previous measures to support the registration system, which contributed to registering 37 drug preparations, and approving 25 new drugs for cancer, diabetes, high blood pressure, and Hepatitis C.